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treat PTCL-not otherwise specified, angioimmunoblastic T-cell lymphoma, adult 
T-cell leukemia/lymphoma, and anaplastic large cell lymphoma patients. There 
was absence of consensus regarding standard therapeutic measures. Randomized 
controlled trials comparing different treatment approaches for PTCL are very lim-
ited due to its rarity and the heterogeneity of subtypes. METHODS: We attempt to 
collect clinical approved evidences for the efficacy and safety of pralatrexate as 
a salvage treatment for relapsed/refractory PTCL by systematic review. Searches 
based on According to National Comprehensive Cancer Network (NCCN) Guidelines 
and explicit inclusion criteria and exclusion criteria are set for literature search-
ing in PubMed, Cochrane Library and Web of Science. We evaluate primary effi-
cacy outcome (ORR and 95% CI), secondary efficacy outcomes (overall survival and 
progression-free survival duration) and safety outcomes. RESULTS: Twenty-four 
studies were initially identified for abstract screening. After further checking by 
two independent reviewers, 11 records eligible for full-text reviews. A total of 351 
relapsed/refractory PTCL patients were investigated from 11 studies. The median age 
for those treated with pralatrexate were ranged from 45 to 61.5. Before ORRs were 
compared, we adjusted the severity of diseases due to heterogeneous distribution 
of PTCL subtypes. CONCLUSIONS: Our study results indicate that pralatrexate is 
the salvage treatment of choice for the heavily pretreated patients.
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OBJECTIVES: In the era of personalized medicine, oncologists seek to tailor treatments 
for their patients based on indicators of differential response to treatment. The objec-
tive of this study was to estimate the survival benefit associated with androgen depri-
vation therapy (ADT) receipt in elderly Medicare patients newly diagnosed with Stage 
4 metastatic (S4M1) prostate cancer across patient subgroups defined by Gleason 
score and age. METHODS: We analyzed elderly men diagnosed with S4M1 prostate 
cancer between 2004-2009 in the SEER-Medicare datasets and followed through 2010 
or until loss to follow-up. An inverse probability weighted Cox proportional hazards 
model with ADT-by-age and ADT-by-Gleason score interaction terms was used to 
estimate overall survival (OS) and prostate cancer-specific survival (PCSS). RESULTS: 
Among 4,691 patients, 3,426 (73%) men received ADT within the first 6 months of 
diagnosis and 1,265 (27%) men did not receive any form of ADT (median follow-up: 17 
months). There were 3,173 total deaths in the cohort, 1,923 (61%) deaths of which were 
due to prostate cancer. Compared to the non-ADT group, ADT users had a 52%, 39%, 
59%, and 62% relative reduction in the risk of all-cause death in men aged 66-70, 71-75, 
76-80, and 80+, respectively (statistically significant; based on stratified hazard ratios 
from the Cox model). A similar trend was observed for PCSS for the age subgroups. 
Compared to the non-ADT group, ADT users had a 54% and 57% relative reduction in 
the risk of all-cause deaths and prostate cancer-specific deaths in men with Gleason 
8-10, respectively. However, the startified hazard ratios for Gleason < 8 showed no OS 
benefit (Gleason 2-6: [1.4 (0.79-2.44)] and Gleason 7: [0.88 (0.68-1.14)] or PCSS benefit 
(Gleason 2-6: [1.09 (0.53-2.20)]; Gleason 7: [1.05 (0.72-1.51)]. CONCLUSIONS: ADT was 
beneficial in terms of OS and PCSS for all age and Gleason score subgroups except 
men with Gleason score 2-6 and 7.
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OBJECTIVES: Statins may have protective effects against hepatocellular can-
cer, but no studies have focused on their clinical interactions with nucleoside 
analogues(NAs) in patients with chronic hepatitis B virus (HBV) infection. The pur-
pose of this study was to investigate the association between the use of NAs, statins 
and the risk of hepatocellular carcinoma (HCC) in HBV-infected patients. METHODS: 
A population-based matched cohort study of 91,265 HBV-infected patients enrolled 
in the Taiwan National Health Insurance Research Database since October, 2003 and 
December, 2010. 18,253 patients with NAs use were 1:4 matched as 73,012 patients 
without NAs use according to index date, age, sex, diabetes, liver cirrhosis, hyper-
tension, hyperlipidemia, biliary tract stones, chronic renal injury, alcohol related 
diseases, and COPD. Cox proportional hazards regression model for drug expo-
sures was employed to evaluate the association between NAs, statin use and HCC 
risk. RESULTS: 2841 patients were diagnosed with HCC during 262489.6 person-
years; the overall incidence rate was 1082.3 cases per 100,000 person-years or 1% per 
year. The mean follow-up time was 2.9 years. We observed a significantly lower risk 
of HCC among NAs users than among non-users (adjusted HR, 0.42; 95%CI, 0.37-0.48) 
after controlling for potential confounders, which was also found in statin users. 
In addition, we found there was a synergistic effect on NAs and statins uses. The 
adjusted HRs were 0.27 (95%CI, 0.12–0.59), 0.42 (95%CI, 0.37–0.48), and 0.62 (95%CI, 
0.47–0.84) for patients with both NAs, statin user, only NAs user, only statin user 
when comparing with non-users. CONCLUSIONS: NAs are effective in suppressing 
HBV replication and in ameliorating HBV related liver disease. Statins may have 
protective effects against hepatocellular cancer, and our study found there was a 
synergistic effect on HCC risk reduction of NAs and statins use.
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with supplementary information from study protocols, clinical study reports, and 
prescribing information. The trials were evaluated for any potential threats to study 
validity, such as selection bias, performance bias, and assessment bias, as well as the 
likelihood for chance effects instead of true effects. A detailed analysis of attrition 
(discontinuation or loss to follow up), which is a frequent issue in oncology studies, 
was also conducted to assess the presence of attrition bias. RESULTS: The integrated 
analysis and three pivotal trials were found to be of high-quality evidence and at 
low risk of bias and chance effects. Important quality features included a robust 
randomization process, high likelihood of patients remaining balanced and blinded 
throughout the study, as well as a high degree of adherence to assigned treatments. 
These and other factors, such as balance in co-interventions and in rates and reasons 
for discontinuation, make bias from attrition unlikely. CONCLUSIONS: The critical 
appraisal confirmed that the results of the integrated analysis and three pivotal trials 
were robust, with denosumab providing clinically meaningful benefit in patients with 
bone metastases from advanced cancer.
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OBJECTIVES: Clinical studies of metformin in certain cancer types have demonstrated 
decreases in incidence and improvements in therapeutic response. Preclinical evi-
dence supports multiple potential molecular pathways through which metformin 
may impart beneficial effects which impede the development and growth of head 
and neck cancer (HNC). We investigated the impact of metformin exposure following 
a diagnosis of HNC on the risk of all-cause mortality in a population-based cohort 
of Italian patients. METHODS: We used the Italian Emilia-Romagna Regional (RER) 
longitudinal healthcare database to conduct a retrospective cohort study following 
approximately 4 million adults (> = 18) from 2003 to 2011. The RER database captures 
de-identified, fully-linkable demographic, hospital discharge including ICD-9 diag-
nostic and procedure codes, outpatient pharmacy, and specialty data for all residents 
of the region. Resection status and metastases were used to stage the HNC patients 
based on surgical procedures and secondary malignancies. Cox proportional hazard 
methods were used to model the covariate-adjusted time-dependent medication 
exposure survival association to minimize potential immortal-time-bias. RESULTS: 
During the study period, we identified 7,872 patients diagnosed with HNC after which 
708 (8.99%) were exposed at some point to metformin and 3,626 (46.1%) died during 
follow-up (median = 2.98 years). Among them, after adjusting for potential confound-
ers, we found no significant association between exposure to metformin and reduced 
risk of all-cause mortality (HR= 1.03, 95% CI: 0.84 – 1.26). CONCLUSIONS: Our large 
population-based cohort study failed to find an advantage in survival outcomes for 
HNC cancer patients exposed to metformin, despite in-vitro mechanistic viability. 
Further research will be critical in clearly defining the role of metformin in HNC 
cancer survival using similar modeling approaches.
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OBJECTIVES: The aim of the study was to identify and characterize long term survival 
population of advanced non–small-cell lung cancer patients treated with immuno-
therapy. METHODS: Data from 717 patients coming from two expanded used program 
and from two randomized trials evaluating the efficacy of CIMAvaxEGF and Vaxira 
in patients with advanced NSCLC, were used. Mixture models were fitted to Overall 
Survival with one or two population components. All analyzes were made using the 
NLMIXED procedure in SAS. We used the diagnostic tools provided by this procedure 
to check the models’ good of fit properties. The characterization of the two popula-
tions based in prognostic factors was done by classification tree models using RPART 
package in R. RESULTS: Two months of overall survival (OS) benefit were showed for 
CIMAvaxEGF and for Vaxira. The optimal mixture model with the fewest number of 
parameters that adequately describes the time survival data is a mixture model with 
2 component distributions. Components represent short-term and long-term survival 
subpopulations. The proportions of the long term population increase with immu-
notherapy in 22% of patients for Vaxira and 18% for CIMAvaxEGF. The OS benefit was 
different for both subpopulation for both vaccines (vaxira: 2.08 months and 8.7 of OS 
benefit for short- and long- term survival populations respectively; CIMAvaxEGF: 1.96 
months and 14.36 months of OS benefit for short- and long- term survival populations 
respectively). The performance status and the age were essential in the classifica-
tion of the two populations. CONCLUSIONS: The results confirm that there are two 
subgroups among NLCLC patients. The separate analysis of subgroups can give more 
power to the evaluation of clinical trials. The use of mixture models in the analysis 
has implications for the design of new clinical trials. The use of classification trees 
allowed a good characterization of the two populations.
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OBJECTIVES: Pralatrexate, the first drug to gain US FDA approval for treatment 
of relapsed/refractory peripheral T-cell lymphomas (PTCL) in 2009, was aimed to 
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OBJECTIVES: The objective of this study is to examine the relationship between 
pre-existing Type 2 Diabetes Mellitus (T2DM) and all-cause mortality among elderly 
Medicare beneficiaries with Colorectal Cancer (CRC), after controlling for other risk 
factors (sex, age, race, co-occurring chronic conditions and office visits prior to 
cancer diagnosis, cancer stage, site, treatment, region and rurality). METHODS: A 
retrospective cohort design was used. The data were derived from the Surveillance, 
Epidemiology, and End Results (SEER) cancer registries linked with Medicare claims 
files. The final study cohort consisted of elderly Medicare beneficiaries (age > 66 
years) who were diagnosed with incident CRC between 2003 and 2008 and continu-
ously enrolled in fee-for-service Medicare Part A and Part B (N = 42,304). Pre-existing 
T2DM was identified with ICD-9-CM (International Classification of Diseases, 9thre-
vision, clinical modification) codes during the 12 months prior to the diagnosis of 
CRC. Time-to-death was calculated in months. Log-rank tests and Cox proportional 
hazards, non-repeatable events regression model were used to test the unadjusted 
and adjusted associations respectively. RESULTS: In our study cohort 29.8% had 
pre-existing T2DM; 44.2% with T2DM died and 41.6% without T2DM died within 
5-years. Median months to death for those with T2DM was 58 (95%CI = 57.9, 58.8) and 
without T2DM was 59 (95%CI = 58.8, 59.1). After adjusting for other risk factors, CRC 
patients with pre-existing T2DM had moderately higher risk for all-cause mortality 
(HR 1.12, 95% CI 1.08, 1.16). Except for tumor location, rurality, region, and hyperten-
sion all other factors were significantly associated with mortality. CONCLUSIONS: 
Elderly Medicare beneficiaries with incident CRC and pre-existing T2DM had mod-
erately higher risk of all-cause mortality. Future research needs to examine whether 
T2DM management reduces the hazards of all-cause mortality among patients with 
T2DM and incident CRC.
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OBJECTIVES: Previous randomized trials and observational studies have shown 
only comparable survival benefits for colon cancer patients undergoing colectomy 
with laparoscopic versus conventional open surgery. Although laparoscopic surgery 
has become a preferred approach, its survival benefits have not been adequately 
examined in a recent colon cancer cohort. We therefore assessed in a real-world 
Medicare population short- and long-term survival among early-stage colon cancer 
patients treated with laparoscopic-assisted colectomy (LAC) versus open colectomy 
(OC). METHODS: In this retrospective observational cohort study, early-stage colon 
cancer patients aged ≥ 65 years who received colectomy within 6 months of diag-
nosis were selected from the Surveillance Epidemiology and End Results-Medicare 
database (2004-2009). Patients undergoing LAC were propensity matched to those 
receiving OC on demographic and clinical characteristics (stage at diagnosis, tumor 
size, and comorbidities). Short-term (1-year) and long-term (5-year) overall survival 
rates, and survival times were assessed using Kaplan-Meier methods for the overall 
cohort and separately by patients diagnosed with local- versus regional-stage dis-
ease. RESULTS: A total of 10,073 early-stage cancer patients met the study inclusion 
criteria (55% female; median age 77.8 years). Of total, 60.2% were diagnosed with 
local-stage and 39.8% with regional-stage disease at diagnosis. The 1-year survival 
did not differ between LAC and OC groups for the overall cohort and local-stage 
patients, but was significantly higher in the LAC group for regional-stage patients 
(98.4% vs. 97.4%; p< 0.05). The 5-year survival was significantly better in the LAC 
(vs. OC) group for the overall cohort (63.2% vs. 59.8%; p< 0.05) and regional-stage 
patients (54.9% vs. 48.5%; p< 0.01). Regional-stage patients treated with LAC also 
had longer survival time (5.5 vs. 4.7 years; p< 0.01). CONCLUSIONS: Results of this 
study indicate that LAC was associated with greater long-term overall survival rate 
and survival time versus OC among elderly early-stage colon cancer patients, par-
ticularly those with regional-stage disease at diagnosis.
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OBJECTIVES: As newer treatment options become available to postmenopausal 
women with HR+/HER2- metastatic breast cancer (mBC), understanding the rela-
tive survival benefit of different treatment options and sequencing is of increas-
ing clinical importance. This study compared overall survival (OS) in patients with 
HR+/HER2- mBC whose 1st-line therapy was endocrine therapy (1st-line endo) 
vs. chemotherapy (1st-line chemo) in real-world settings. METHODS: Data were 
extracted from a community oncology electronic medical records database from 
Altos Solutions. Eligible patients were postmenopausal women, with ≥ 1 medical 
record with a BC diagnosis, confirmed HR+/HER2- status, and 1st mBC diagnosis 
(index date) after July 1, 2012. OS between 1st-line endo and 1st-line chemo patients 
was compared using cumulative proportion of deaths and Cox proportional hazard 
regressions controlling for age, race, region, insurance type, comorbidities, disease 
recurrence, and metastatic sites. RESULTS: Among the 1,051 patients meeting the 
eligibility criteria, 676 (64.3%) received 1st-line endo and 375 (35.7%) received 1st-
line chemo. 1st-line endo patients were older (68.1 vs. 64.4 years, p< 0.001) and were 
more often Caucasian (74.1% vs. 65.9%, p= 0.005) compared with 1st-line chemo 
patients. Site of metastases was known in 57.5% of 1st-line endo and 59.2% of 
1st-line chemo patients, with bone being the most common site (48.8% vs. 40.3%, 
p= 0.008). The cumulative proportion of deaths was 5.9% vs. 10.7% (p= 0.005), 10.4% 
vs. 14.7% (p= 0.039), and 12.0% vs. 17.3% (p= 0.016) at 6, 12, and 18 months, respec-
tively. Patients receiving 1st-line endo had better OS at 6 (adjusted hazard ratio [HR]: 
OBJECTIVES: Basal Cell Carcinoma (BCC), a subset of non-melanoma skin cancer 
(NMSC), is the most common cancer in the United States. Previous studies using 
secondary data have been unable to characterize the BCC population, as they were 
completed prior to the release of BCC-specific ICD-9 codes in 2011. The objective 
of this study was to estimate the incidence and prevalence of BCC in a commer-
cially insured US population. METHODS: This was a retrospective study using the 
MarketScan Commercial and Medicare Supplemental Database. Patients included 
were aged ≥ 18 years with ≥ 2 claims for BCC in any position, separated by 60 ≤ 
days ≤ 180 in the identification period 10/1/11 to 9/30/12. Patients were continu-
ously enrolled in medical and pharmacy benefits in the 12 months prior to and 
following the first observed claim (index date). The cohort was further categorized 
as having incident or prevalent BCC, based on the absence or presence of a NMSC 
diagnosis code in the year prior to the index date. Descriptive statistics were per-
formed on baseline demographics and clinical characteristics. RESULTS: A total 
of 19,704 patients with BCC were identified, of whom 12,299 (62.4%) were incident 
and 7,405 (36.6%) were prevalent cases. The majority of patients were male (overall: 
59%, incident: 55%, and; prevalent: 67%, respectively). The mean age (SD) of the BCC 
cohort was 66 (13.8) and patients with incident disease were younger 64 (13.7) than 
patients with prevalent disease 69 (13.5). Mean Charlson Comorbidity Index scores 
were higher in the prevalent cohort (1.5 vs 1.0) and were largely driven by rates of 
malignancy (21.9% vs. 12.6%), diabetes (20.1% vs. 17.7%), and chronic obstructive 
pulmonary disorder (12.8% vs. 10.8%). CONCLUSIONS: In this commercially insured 
population, patients with prevalent BCC are more likely to be male, older, and have 
higher rates of comorbidities than patients with incident disease.
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OBJECTIVES: Explore epidemiology and drug treatment of radioactive iodine-refrac-
tory differentiated thyroid cancer (RR-DTC) in EU5. METHODS: Epidemiology of 
RR-DTC was derived from the Kantar Health (KH) CancerMPact database, sources 
for which include country specific cancer registries, published scientific studies 
and proprietary physician surveys comprising 81 doctors seeing a total of 3,985 
patients per month. Data specific to treatment of RR-DTC was derived from patient 
chart review studies conducted by KH. Age and gender specific incidence rates, 
annual stage specific progression rates and annual stage specific survival rates 
are used to calculate total number of surviving patients at a specific stage up to 
10 years after diagnosis. RESULTS: Incidence of thyroid cancer ranged between 5 
- 20 per 100K population across EU-5 (UK-4.8, Germany-8.4, France-13.4, Italy-20.3, 
Spain-7.2). Among all thyroid patients, % DTC showed less variation: 76% (UK), 83% 
(Germany), 87% Italy, 88% (Spain), 91% (France). Among DTC, % RR was very similar 
(range 26% - 33%). Among RR DTC, 23% received watch and wait, 33% non-systemic 
management and 44% systemic therapy. Among those receiving systemic therapy, 
48% received chemotherapy, 46% received tyrosine kinase inhibitors (TKI) and 6% 
BRAF inhibitors. Among those receiving chemotherapy, 50% received doxorubicin, 
either as monotherapy or part of a multi drug regimen and 20% received cisplatin. 
Among those receiving a TKI, 51% received sorafenib, 28% sunitinib. CONCLUSIONS: 
Among RR DTC patients treated with systemic therapy, chemotherapy and TKIs 
are used most often. The most common chemotherapy is a doxorubicin containing 
regimen and sorafenib is the most common TKI used.
PCN27
boNe PaiN, skeletal related eveNts aNd oPioid use iN PatieNts WitH 
Prostate CaNCer aNd boNe metastases
Valderrama A.1, Eapen S.2, Hennessey K.A.3, Jones C.4, Wen L.1, Germino J.5, Duh M.S.6
1Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 2Analysis Group (at the time of study), 
Boston, MA, USA, 3Analysis Group, Boston, MA, USA, 4Analysis Group, In, Boston, MA, USA, 
5Bayer Healthcare, Whippany, NJ, USA, 6Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: Prostate cancer (PC) patients with bone metastases experience symp-
toms including debilitating pain that is associated with increased morbidity and 
mortality. Opiates in conjunction with other treatments are recommended for the 
management of severe pain, but real world data on their use in PC are limited. This 
study estimates the prevalence of and predictors for opioid use in PC patients with 
bone metastases. METHODS: Electronic medical records (EMR) from US community 
oncology clinics captured in OncoEMR® database were used to identify PC patients 
with bone metastases. Opioid use was identified from EMR, while evidence of bone 
pain and skeletal-related events (SREs), including pathological fracture, surgery, radio-
therapy to bone and spinal cord compression were extracted from patients’ medical 
charts. Prevalence of opioid use was evaluated. Predictors for opioid vs. non-opioid 
analgesic use for pain were identified using a multivariate logistic model. RESULTS: 
In the study cohort of 1,520 PC patients with bone metastases, the average age was 
73.6 years and mean follow-up from bone metastases was 13.8 months. In the sub-
set with evidence of bone pain (N= 927), 63% were opioid users, of whom 14% were 
chronic users. Multivariate regression analyses revealed that SREs significantly 
increased the opioid use risk by 3.21-fold (95% CI: 2.38-4.32), with the following addi-
tional significant risk factors: Medicare vs. other/no insurance (OR= 1.54, 95% CI: 1.13, 
2.10), chemotherapy (OR= 3.34, 95% CI: 2.17, 5.13), and NSAIDs use (OR= 1.90, 95% CI: 
1.25, 2.88). CONCLUSIONS: SREs are a significant predictor for opioid use. 37% of 
the patients with bone pain had no documented use of opioids. Pain and symptom 
palliation is a significant management issue in PC. It is important to choose appropri-
ate treatments for patients that delay or prevent SREs and effectively control pain.
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